Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) has been generally considered a genetic disease (disorder) with an aggressive tumor entity of highly proliferative malignant lymphoid cells. However, in recent years, significant advances have been made in the elucidation of the ALL-associated processes. Thus, we understand that histone acetylation is involved in the permanent changes of gene expression controlling ALL developmental outcomes. In this article, we will focus on histone acetylation associated with ALL, their implications as biomarkers for prognostic, and their preclinical and clinical applications.

• Publication year

  2015

• Venue

  Clinical Epigenetics

• Publication date

  2015-11-04

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1186/s13148-015-0151-8PMID 26543507PMCID 4634719
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

  2016cited by this paper
• Histone deacetylases and mechanisms of regulation of gene expression.

  2015cited by this paper
• Epigenetics in T‐cell acute lymphoblastic leukemia

  2015cited by this paper
• Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

  2014cited by this paper
• Understanding the relationship between DNA methylation and histone lysine methylation

  2014cited by this paper
• Targeting bromodomains: epigenetic readers of lysine acetylation

  2014cited by this paper
• HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A

  2014cited by this paper
• The growing landscape of lysine acetylation links metabolism and cell signalling

  2014cited by this paper
• Effect of valproic acid on the proliferation and apoptosis of the human melanoma G-361 cell line.

  2014cited by this paper
• Cancer epigenetics drug discovery and development: the challenge of hitting the mark.

  2014cited by this paper
• Regulation of nucleosome dynamics by histone modifications

  2013cited by this paper
• The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia.

  2013cited by this paper
• Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB

  2013cited by this paper
• Relapsed childhood acute lymphoblastic leukaemia.

  2013cited by this paper
• GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia

  2013cited by this paper
• Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells

  2013cited by this paper
• Cancer Epigenetics: New Therapies and New Challenges

  2013cited by this paper
• Differential mRNA Expression Levels of Human Histone-Modifying Enzymes in Normal Karyotype B Cell Pediatric Acute Lymphoblastic Leukemia

  2013cited by this paper
• [Effect of valproic acid sodium on proliferation and apoptosis of acute T-lymphoblastic leukemia Jurkat cells].

  2013cited by this paper
• Increased activity of histone deacetylases in childhood acute lymphoblastic leukaemia and acute myeloid leukaemia: support for histone deacetylase inhibitors as antileukaemic agents

  2012cited by this paper
• HDAC modulation and cell death in the clinic.

  2012cited by this paper
• Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

  2012cited by this paper
• The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

  2012cited by this paper
• A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

  2012cited by this paper
• CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia

  2012cited by this paper
• Emerging Pharmacotherapies for Adult Patients with Acute Lymphoblastic Leukemia

  2012cited by this paper
• Preclinical activity of LBH 589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

  2012cited by this paper
• Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?

  2012influential reference
• DNA methylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL

  2012cited by this paper
• Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

  2012cited by this paper
• CREBBP mutations in relapsed acute lymphoblastic leukaemia

  2011influential reference
• Co-Regulation of Histone-Modifying Enzymes in Cancer

  2011cited by this paper
• A decade of exploring the cancer epigenome — biological and translational implications

  2011cited by this paper
• Deacetylation of nonhistone proteins by HDACs and the implications in cancer.

  2011cited by this paper
• A unique chromatin signature uncovers early developmental enhancers in humans

  2011cited by this paper
• Glioblastoma stem cells

  2011cited by this paper
• Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL)

  2011cited by this paper
• Genetic Inactivation of the PRC2 Complex in T-Cell Acute Lymphoblastic Leukemia

  2011cited by this paper
• Charting histone modifications and the functional organization of mammalian genomes

  2011cited by this paper
• HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo

  2011cited by this paper
• Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.

  2011cited by this paper
• The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias

  2011cited by this paper
• Valproic acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway.

  2011cited by this paper
• Molecular and Therapeutic Potential and Toxicity of Valproic Acid

  2010cited by this paper
• Histone variants — ancient wrap artists of the epigenome

  2010cited by this paper
• Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers

  2010cited by this paper
• Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy

  2010cited by this paper
• Tuning acetylated chromatin with HAT inhibitors: A novel tool for therapy

  2010cited by this paper
• Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients

  2010cited by this paper
• Valproic acid in the complex therapy of malignant tumors.

  2010cited by this paper
• Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development

  2010cited by this paper
• Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells

  2010cited by this paper
• research paper: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia

  2010cited by this paper
• Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.

  2010cited by this paper
• The many roles of histone deacetylases in development and physiology: implications for disease and therapy

  2009cited by this paper
• Linking DNA methylation and histone modification: patterns and paradigms

  2009cited by this paper
• Acetylation of non-histone proteins modulates cellular signalling at multiple levels.

  2009cited by this paper
• Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program

  2009cited by this paper
• Histone deacetylase inhibitors as anti-neoplastic agents.

  2009cited by this paper
• Anti‐leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro

  2009cited by this paper
• Development of vorinostat: current applications and future perspectives for cancer therapy.

  2009influential reference
• Romidepsin for the treatment of cutaneous T-cell lymphoma.

  2009cited by this paper
• Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

  2009cited by this paper
• Combinatorial patterns of histone acetylations and methylations in the human genome

  2008cited by this paper
• Modulation of TRAIL-induced apoptosis by HDAC inhibitors.

  2008cited by this paper
• Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

  2008cited by this paper
• ICER expression inhibits leukemia phenotype and controls tumor progression

  2008cited by this paper
• PI3‐K/Akt‐dependent activation of cAMP‐response element‐binding (CREB) protein in Jurkat T leukemia cells treated with TRAIL

  2008cited by this paper
• Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells.

  2007cited by this paper
• Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

  2007cited by this paper
• The epigenomics of cancer.

  2007cited by this paper
• Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma

  2007cited by this paper
• Histone Deacetylase Inhibitors: Overview and Perspectives

  2007cited by this paper
• Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

  2007cited by this paper
• HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway.

  2007cited by this paper
• The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.

  2007cited by this paper
• Histone deacetylase inhibitors: molecular mechanisms of action

  2007cited by this paper
• The cancer epigenome--components and functional correlates.

  2006cited by this paper
• Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

  2006influential reference
• Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia

  2006cited by this paper
• A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

  2006cited by this paper
• Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.

  2006cited by this paper
• Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors

  2005cited by this paper
• Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid.

  2005cited by this paper
• Chromatin modifying activity of leukaemia associated fusion proteins.

  2005cited by this paper
• The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce Apoptosis in Human Leukemia Cells

  2004cited by this paper
• Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.

  2004cited by this paper
• Disease-related potential of mutations in transcriptional cofactors CREB-binding protein and p300 in leukemias.

  2004cited by this paper
• The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

  2003cited by this paper
• FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.

  2002cited by this paper
• The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.

  2002cited by this paper
• Structure of histone acetyltransferases.

  2001cited by this paper
• Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

  2001cited by this paper
• Translating the Histone Code

  2001cited by this paper
• Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

  2000cited by this paper
• Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP.

  2000cited by this paper
• Regulation of chromatin structure by site-specific histone H3 methyltransferases

  2000cited by this paper
• Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

  1999cited by this paper
• The bromodomain: a chromatin-targeting module?

  1999cited by this paper
• Signaling to chromatin through histone modifications: how clear is the signal?

  1998cited by this paper

• Identification of A p300-SP1-BRD4 Transcriptional Axis as a Key Driver of AR Hyperactivation in Polycystic Ovarian Syndrome.

  2026cites this paper
• Biological Activity and Structural Biology of Current KAT6A Inhibitor Chemotypes.

  2026cites this paper
• Neutrophils secrete exosome-associated DNA to resolve sterile acute inflammation

  2025influential citation
• A comprehensive proteome structural analysis suggests undiscovered functional domains in ocean archaea

  2025cites this paper
• Potential role of short-chain fatty acids in the pathogenesis and management of acute lymphocytic leukemia

  2023influential citation
• Comprehensive analysis of the proximity-dependent nuclear interactome for the oncoprotein NOTCH1 in live cells

  2023cites this paper
• A Comprehensive Overview of Recent Advances in Epigenetics in Pediatric Acute Lymphoblastic Leukemia

  2022cites this paper
• Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies

  2022cites this paper
• Genome-wide CRISPR/Cas9 screening identifies determinant of panobinostat sensitivity in acute lymphoblastic leukemia

  2022cites this paper
• Contributions of epigenetic inheritance to the predisposition of major psychiatric disorders: theoretical framework, evidence, and implications.

  2022cites this paper
• Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL

  2021cites this paper
• Therapeutic Interaction of Apatinib and Chidamide in T-cell Acute Lymphoblastic Leukemia through Interference with Mitochondria Associated Biogenesis and Intrinsic Apoptosis

  2021cites this paper
• Comprehensive analysis of lysine crotonylation modification in patients with chronic renal failure

  2021cites this paper
• The Effect of CDK6 Expression on DNA Methylation and DNMT3B Regulation

  2020cites this paper
• Cancer Treatment: An Epigenetic View

  2020cites this paper
• The Effect of 6-Thioguanine on Proliferation, Viability and Expression of the Genes DNMT 3A, DNMT 3B and HDAC3 in Lymphoid Cancer Cell Line Nalm6

  2020cites this paper
• Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.

  2020cites this paper
• Epigenetic modifications in acute lymphoblastic leukemia: From cellular mechanisms to therapeutics.

  2020cites this paper
• Apoptosis Induced by Prednisolone Occurs without Altering the Promoter Methylation of BAX and BCL-2 Genes in Acute Lymphoblastic Leukemia Cells CCRF-CEM

  2020cites this paper
• Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy

  2020cites this paper
• Combination of Pan-HDAC Inhibitor and COX-2 Inhibitor Produces Synergistic Anticancer Effects in Human Salivary Adenoid Cystic Cancer Cells.

  2019cites this paper
• Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.

  2019cites this paper
• Targeting epigenetics for cancer therapy

  2019cites this paper
• Identification of Compounds That Inhibit Estrogen-Related Receptor Alpha Signaling Using High-Throughput Screening Assays

  2019cites this paper
• Epigenetic Landscape in Leukemia and Its Impact on Antileukemia Therapeutics

  2019cites this paper
• Retinoic Acid Receptors in Acute Myeloid Leukemia Therapy

  2019cites this paper
• Comprehensive analysis of lysine crotonylation in proteome of maintenance hemodialysis patients

  2018cites this paper
• Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases

  2018cites this paper
• Histone Deacetylation in the Promoter of p16 Is Involved in Fluoride-Induced Human Osteoblast Activation via the Inhibition of Sp1 Binding

  2018cites this paper
• Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition

  2018cites this paper
• Nouvelle thérapie épigénétique dans le traitement du neuroblastome pédiatrique

  2018cites this paper
• A Trichostatin A (TSA)/Sp1-mediated mechanism for the regulation of SALL2 tumor suppressor in Jurkat T cells.

  2018cites this paper
• Benzene metabolite 1,2,4-benzenetriol changes DNA methylation and histone acetylation of erythroid-specific genes in K562 cells

  2018cites this paper
• Epigenetic modifications in chronic myeloid leukemia cells through ruxolitinib treatment

  2018cites this paper
• Epigenetic alterations in acute lymphoblastic leukemia

  2017cites this paper
• [Epigenetic alterations in acute lymphoblastic leukemia].

  2017cites this paper
• Gene-expression profiling to reveal pathogenic mechanisms in disease

  2017influential citation
• Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN

  2017cites this paper
• An epigenetic view of developmental diseases: new targets, new therapies

  2016cites this paper
• Proscillaridin A effects on histone acetylation and C-MYC degradation in acute lymphoblastic leukemia

  2016influential citation
• Protein Arginine Methyltransferase 5 as a Driver of Lymphomagenesis

  2016cites this paper